Mylan has agreed to pay $465 million after lawmakers and health officials said it wrongly classified EpiPen as a generic product. The classification allowed the pharmaceutical company to pay lower rebates for Medicaid program.
Mylan has agreed to pay $465 million after lawmakers and health officials said it wrongly classified EpiPen as a generic product. The classification allowed the pharmaceutical company to pay lower rebates for Medicaid program.
Share this Article
Recommended